Lana

Investors sent its shares down about 20% this week.

All in all, Novo thinks revenue could fall by as much as 13% this year, and it can't pin that solely on knockoff rivals and steeper discounts.

Eli Lilly, after all, sells similar weight loss drugs, and the American firm has pulled ahead with more effective treatments and a faster manufacturing ramp.

That sets Lilly up to better handle this new pricing pressure, which is why the firm still expects its revenue to climb this year by as much as 27%.

No wonder investors have picked a favorite.

Lilly's shares are up about 20% over the past year, while Novo's have slumped.

That's it for today.

I'm Lana.

I'll see you next week.

Hey, I'm Lana with your daily brief for Friday, February 6th.

Coming up, Amazon's incomings were a pretty package, but its outgoings weren't exactly what investors ordered.

And Elon Musk is taking SpaceX public, and he wants the firm to skip the stock market index waiting list.

We'll also check in with Carl to get his answers to your burning questions.

More on the way, but first, a word from Guy at Finimize HQ.

Amazon made 14% more revenue than the same time the year before, a slightly better result than analysts expected.

Mind you, profit still came in a touch below forecasts.

That was mainly thanks to a solid performance from Amazon Web Services.

Revenue there grew by nearly a quarter compared to the year before, better than predicted.

Ad sales came in higher than analysts had penciled in, too.

Together, that reinforces Amazon's reputation of doing more than just retail.